{"id":"W2618666290","doi":"10.1016/j.pharmthera.2017.05.010","title":"Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer","year":2017,"lang":"en","type":"review","venue":"Pharmacology & Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Celldex Therapeutics; McGill University; U.S. Department of Defense","keywords":"Clinical trial; Medicine; Context (archaeology); Metastasis; Cancer; Antibody-drug conjugate; Cancer research; Oncology; Bioinformatics; Internal medicine; Pharmacology; Immunology; Biology; Monoclonal antibody; Antibody","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001626283,0.0004105764,0.001261742,0.00009136357,0.0003645912,0.0000207897,0.000228721,0.0001440373,0.00008627875],"category_scores_gemma":[0.000001266794,0.0001961205,0.0002160122,0.00005232935,0.0004019775,0.00002670749,0.00005282766,0.0002998626,0.000001677184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001194092,"about_ca_system_score_gemma":0.001027845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002508175,"about_ca_topic_score_gemma":0.00001096199,"domain_scores_codex":[0.9986061,0.00009641644,0.0003953007,0.0002906553,0.0002217679,0.0003897866],"domain_scores_gemma":[0.9987062,0.0003822988,0.0004079879,0.0001895731,0.0001994568,0.0001145373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004163642,0.0002228219,0.0001401579,0.006645456,0.004644358,0.00002084577,0.0002907865,1.966334e-7,0.000007813106,0.00002207079,0.0007515808,0.9868376],"study_design_scores_gemma":[0.001270433,0.0006494199,0.00005059174,0.001135921,0.008103171,0.00003783423,0.00008359788,0.00002894526,0.00003871795,0.000003596087,0.9884082,0.0001895865],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002445231,0.9940736,0.000004902905,0.002447532,0.0008994473,0.001984883,0.0002438266,0.00001232396,0.00008894104],"genre_scores_gemma":[0.00001737519,0.9952547,0.0001526825,0.0003289506,0.001502014,0.0008398862,0.0001331007,0.00005020971,0.001721094],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9876566,"threshold_uncertainty_score":0.7997563,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4104595518385268,"score_gpt":0.519545667675315,"score_spread":0.1090861158367881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}